CN1042298C - Pharmaceutical preparations and process for preparing same - Google Patents
Pharmaceutical preparations and process for preparing same Download PDFInfo
- Publication number
- CN1042298C CN1042298C CN 90106613 CN90106613A CN1042298C CN 1042298 C CN1042298 C CN 1042298C CN 90106613 CN90106613 CN 90106613 CN 90106613 A CN90106613 A CN 90106613A CN 1042298 C CN1042298 C CN 1042298C
- Authority
- CN
- China
- Prior art keywords
- weight
- podophyllotoxin
- preparation
- treatment
- suspended
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims abstract description 29
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims abstract description 29
- 229960001237 podophyllotoxin Drugs 0.000 claims abstract description 29
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 16
- 206010059313 Anogenital warts Diseases 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000003240 coconut oil Substances 0.000 claims description 9
- 235000019864 coconut oil Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 8
- 229960003415 propylparaben Drugs 0.000 description 8
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 235000010199 sorbic acid Nutrition 0.000 description 7
- 239000004334 sorbic acid Substances 0.000 description 7
- 229940075582 sorbic acid Drugs 0.000 description 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- -1 Polyethylene Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention refers to new pharmaceutical preparations and process thereof for the treatment of psoriasis and condyloma acuminata, and containing podophyllotoxin in combination with a liquid triglyceride.
Description
The present invention relates to contain the preparation of drug combination method of the cream forms of podophyllotoxin.The preparation of making is used for the treatment of psoriasis and condyloma acuminatum.
EP-B1-119 852 discloses a kind of podophyllotoxin preparation that is used for the treatment of condyloma acuminatum.These preparations contain podophyllotoxin and at least a dihydroxylic alcohols that is selected from aklylene glycol and poly alkylene glycol.
US-A-4,788,216 disclose the psoriasic method of a kind of treatment, are to carry out administration with podophyllotoxin.Wherein mention the form that can adopt emulsifiable paste, but do not provide concrete medicament.
Existing podophyllotoxin medicament drug effect and stable aspect need be improved.And this improvement is achieved by the present invention.
The purpose of this invention is to provide a kind of preparation that is used for the treatment of psoriasis and condyloma acuminatum with good clinical effectiveness and stability.
According to the present invention, find that unexpectedly the compositions that podophyllotoxin and one or more triglyceride are formed can form stable formulation, it has good curative effect to psoriasis and condyloma acuminatum, and side effect is very little.This preparation is emulsifiable paste or ointment form preferably, wherein together emulsifying of triglyceride and water.
When being used for the treatment of psoriasis, said preparation should contain 0.02-1% (weight) podophyllotoxin, better contains 0.05-0.5% (weight) podophyllotoxin, preferably contains about 0.1% (weight) podophyllotoxin.Because of needing the very long cycle usually in the treatment psoriasis, it is very important keeping the podophyllotoxin of low concentration, to avoid undesirable side effect.
In this description and claims, except as otherwise noted, all percents all are percetages by weight, and all the gross weight with preparation is a benchmark.
When being used for the treatment of condyloma acuminatum, said preparation should contain 0.01-1% (weight) podophyllotoxin, is preferably to contain 0.15-0.5% (weight) podophyllotoxin, preferably contains about 0.3% (weight) podophyllotoxin.
Described preparation contains one or more triglyceride of 3-15% (weight) usually, preferably contains about 10% (weight).Preferably has the medium chain liquid triglycerides of (each strand contains 6-14 carbon atom), preferably the triglyceride of suffering/capric acid (fractionated Oleum Cocois).A kind of these commercially available class fractionated coconut oil commodity are called Miglyol.
Except podophyllotoxin and one or more liquid triglycerides, described preparation also contains 50-85% (weight) water, and auxiliary substance, as emulsifying agent, and shop agent in morning, antiseptic, antioxidant and maintenance pH are in the buffer agent of given level.Be used for the treatment of psoriasic preparation and also can contain dihydroxylic alcohols or polyhydric alcohol.
The emulsifying agent that is suitable for comprises the product that following row trade name is sold, Eomlsifier E2155 (Polyethylene Glycol (7) stearyl ether, Polyethylene Glycol (10) stearyl ether and octadecanol), Brij 72 (Polyethylene Glycol (2) stearyl ether), Brij 721 (Polyethylene Glycol (21) stearyl ether), Arlatone 983 s (Polyethylene Glycol (5) tristerin) and Arlacel 582 (Polyethylene Glycol-glycerol-isostearic acid Isosorbide Dinitrate).Certainly be not limited to above-mentionedly enumerate these.Other nonionic emulsifier with similar HLB value (hydrophile-lipophile balance value) also can adopt.The consumption of emulsifying agent is can obtain required emulsifying effectiveness degree of being.Those of ordinary skill in the art just can determine this consumption at an easy rate by simple routine experimentation, and according to the concrete emulsification system that is adopted, generally between 3-10% (weight), this value is not critical to the consumption of emulsifying agent.
The effect of spreading agent is to help it to sprawl when preparation being coated onto on skin or the mucosa.A kind of known this class reagent is isopropyl myristate, and other similar agents also is known to those skilled in the art.The consumption of shop agent in morning can reach about 5% (weight).
Antiseptic and antioxidant are to be used for stablizing said preparation, prevent deleterious external action, as microorganism and oxygen.The antiseptic that is suitable for comprises methyl butex (4-methyl hydroxybenzoate), propylparaben (4-nipasol) and sorbic acid.The consumption of antiseptic can reach about 0.5% (weight) usually, preferably is no more than 0.2% (weight).The antioxidant that is suitable for comprises tert-butyl group hydroxyanisol, tert-butyl group hydroxy-methylbenzene, and ascorbic acid and derivant thereof are as ascorbic palmitate.But other suitable antioxidant is also known by the ability technical staff.The consumption of antioxidant seldom is no more than 0.2% (weight) usually.
Avoid it that chemical change takes place in order to stablize podophyllotoxin, the pH value of described preparation should be in acidic region, usually between 2-6, is preferably between the 2.6-3.5.Realize this requirement by adding suitable acid or sour buffer agent (as phosphoric acid).Other acid or sour buffer agent that is suitable for also is well known to those skilled in the art.Self-evident, used acid or sour buffer agent must be medicinal acceptable.The consumption of above-mentioned acid or sour buffer agent should make final preparation reach required pH value.
This area other additives known commonly used also can be used in preparation of the present invention.
Above-mentioned preparation is the affected part that topical arrives the psoriatic.When being used for the treatment of condyloma acuminatum, said preparation is part, vagina (tunica vaginalis of testis) or anum administration.Consumption and frequency of administration are decided according to patient's age, health status, distress level and other factor by the doctor.
In clinical trial, prove that pharmaceutical preparation of the present invention has higher activity, does not have or few side effects simultaneously.
For the masculinity and femininity patient who suffers from condyloma acuminatum, Most patients only just can heal entirely through the topical therapeutic of several weeks.In addition, adopt emulsifiable paste of the present invention can reduce treatment cycle.Compare with placebo, the statistics difference is very significant (P=＜0.05).
In treatment psoriasis process, patient's topical application every day with desquamation and scleroma symptom takes an evident turn for the better after several weeks for twice.Each patient all treats in its specific affected part, and other untreated position in contrast.After only around the treatment, emulsifiable paste of the present invention is compared with placebo and is demonstrated excellent effect.This effect says it is very significant (P=＜0.05) from the statistics angle.
In both cases, only observe minimum side effect.
Following example further specifies the present invention, wherein provides some preparations of the present invention.These examples are not construed as limiting the scope of the invention.
In the following emulsifiable paste process of preparation, water and fat are to mix respectively separately and heat mutually.Then water is added to fat mutually in, then add the active component that is suspended in one or more liquid triglycerides.With this mixture homogenization, stir and cooling, obtain required emulsifiable paste.
Example 1 is used for the treatment of the emulsifiable paste of condyloma acuminatum
The fat restriction or checking relation in five elements
Emuolgator?E-2155 8
Hexadecanol 2
Octadecanol 2
Isopropyl myristate 2
Liquid paraffin 3
Fractionated coconut oil 10
Butylated hydroxyanisole (BHA) 0.008
Water
Water 72.34
Methyl butex 0.10
Propylparaben 0.03
Phosphatase 11 M 0.1
Sorbic acid 0.12
Active component
Podophyllotoxin 0.3
Example 2 is used for the treatment of psoriasic emulsifiable paste
The fat restriction or checking relation in five elements
Protegin?WX 22
Fractionated coconut oil 10
Isopropyl myristate 3
Water
Water 59.05
Methyl butex 0.10
Propylparaben 0.03
Propylene glycol 5
Phosphatase 11 M 0.1
MgSO
4·7H
2O 0.5
Sorbic acid 0.12
Active component
Podophyllotoxin 0.1
ProteginWX is the emulsification preparation that is used for emulsifiable paste, and it is the mixture of vaseline, ceresine, castor oil hydrogenated, glyceryl oleate, polyglycereol (4) stearate and tert-butyl group hydroxy-methylbenzene.
Example 3
The fat restriction or checking relation in five elements
Emulsifier?W-2155 8
Hexadecanol 2
Octadecanol 2
Fractionated coconut oil 15
Liquid paraffin 2
Butylated hydroxyanisole (BHA) 0.008
Water
Water 69.64
Methyl butex 0.10
Propylparaben 0.03
Phosphatase 11 M 0.1
Sorbic acid 0.12
Active component
Podophyllotoxin 1
Example 4
The fat restriction or checking relation in five elements
Brij?72 3
Brij?721 2
Hexadecanol 2
Stearic acid 1.5
Fractionated coconut oil 9
Butylated hydroxyanisole (BHA) 0.008
Water
Water 81.64
Methyl butex 0.10
Propylparaben 0.03
Phosphatase 11 M 0.1
Sorbic acid 0.12
Active component
Podophyllotoxin 0.5
Example 5 is used for the treatment of the emulsifiable paste of condyloma acuminatum
The fat restriction or checking relation in five elements
Arlatone?983S 5
Hexadecanol 2
Stearic acid 1.5
Fractionated coconut oil 3
Liquid paraffin 2
Butylated hydroxyanisole (BHA) 0.008
Water
Water 82.10
Methyl butex 0.10
Propylparaben 0.03
Phosphatase 11 M 0.1
Propylene glycol 4
Sorbic acid 0.12
Active component
Podophyllotoxin 0.04
Example 6
The fat restriction or checking relation in five elements
Arlacel?582 10
Isopropyl myristate 3
Liquid paraffin 10
Fractionated coconut oil 12
Butylated hydroxyanisole (BHA) 0.008
Water
Water 59.89
Propylene glycol 4
MgSO
4·7H
2O 0.5
Phosphatase 11 M 0.1
Methyl butex 0.10
Propylparaben 0.03
Sorbic acid 0.12
Active component
Podophyllotoxin 0.25
Claims (8)
1. method for preparing the pharmaceutical composition of the cream forms that contains podophyllotoxin, it is characterized in that its contained 0.01-1% (weight) podophyllotoxin is one or more liquid triglycerides that are suspended in the 3-15% (weight) that each molecule contains the medium chain of 6-14 carbon atom, then that this triglyceride and water is together emulsified.
2. according to the method for claim 1, it is characterized in that the pH value of compositions is adjusted to 2-6.
3. according to the method for claim 2, it is characterized in that the pH value of compositions is adjusted to 2.6-3.5.
4. according to the method for claim 1, preparation is used for the treatment of psoriasic pharmaceutical composition, the method is characterized in that the podophyllotoxin with 0.05-0.5% (weight) is suspended in the liquid triglycerides.
5. according to the method for claim 4, it is characterized in that the podophyllotoxin of 0.1% (weight) is suspended in the fractionated coconut oil of 10% (weight).
6. according to the method for claim 1, preparation is used for the treatment of the pharmaceutical composition of condyloma acuminatum, the method is characterized in that the podophyllotoxin with 0.15-0.5% (weight) is suspended in the liquid triglycerides.
7. according to the method for claim 6, it is characterized in that the podophyllotoxin of 0.3% (weight) is suspended in the fractionated coconut oil of 10% (weight).
8. according to the method for claim 1, it is characterized in that the antioxidant that will be no more than 0.2% (weight) joins in the compositions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH262489 | 1989-07-31 | ||
| CH8902624-9 | 1989-07-31 | ||
| SE89026249 | 1989-07-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1049102A CN1049102A (en) | 1991-02-13 |
| CN1042298C true CN1042298C (en) | 1999-03-03 |
Family
ID=4237948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 90106613 Expired - Lifetime CN1042298C (en) | 1989-07-31 | 1990-07-30 | Pharmaceutical preparations and process for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1042298C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427082C (en) * | 2005-08-02 | 2008-10-22 | 盛华（广州）医药科技有限公司 | Application of hydroxybenzoate and analogue thereof in preparing medicament for preventing and treating viral infection |
| EP2532326B1 (en) * | 2011-06-09 | 2016-03-30 | Paul Hartmann AG | Wound dressing comprising non-woven and salve basis for negative pressure therapy |
-
1990
- 1990-07-30 CN CN 90106613 patent/CN1042298C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1049102A (en) | 1991-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1075722C (en) | Fungicidal compositions containing bifonazole | |
| CN1090509A (en) | Pharmaceutical composition | |
| CN1172674C (en) | A system that promotes penetration and reduces irritation | |
| CN1108654A (en) | Methods of treating menstrual symtoms and compositions therefore | |
| CN1713923A (en) | Pharmaceutical compositions containing modified excipients | |
| CN1156407A (en) | topical ketoconazole emulsion | |
| CN1266370A (en) | Activated vitamin D3 emulsion-type lotions | |
| CN1522145A (en) | Compositions containing antifungal agents for the treatment of vulvovaginitis and vaginosis | |
| CN1481812A (en) | povidone iodine spray | |
| EA038882B1 (en) | Apremilast pharmaceutical compositions | |
| CN1109884A (en) | Methods of inhibiting myeloperoxidase activity | |
| CN1265838C (en) | Injectable veterinary composition for small animals | |
| CN1042298C (en) | Pharmaceutical preparations and process for preparing same | |
| CN1153571C (en) | External therapeutic composition for dermatitis | |
| CN1507858A (en) | Flrorinated chloromycetin containing liquid preparation for animal | |
| CN1284864A (en) | New formulations for pain control | |
| CN1399542A (en) | Pharmaceutical carrier formulation | |
| CN1732969A (en) | Ointment with clindamycin and metronidazole and method for preparing the same | |
| CN1748758A (en) | Dragon's blood gel preparation and its preparing method | |
| CN1376460A (en) | Fat emulsion for injection and its preparing process | |
| CN1036046C (en) | Preparation for cantharidia liposoluble pharmaceutics | |
| CN1160128C (en) | Antiviral formulations containing propylene glycol and isopropyl alkanoate | |
| CN1309557A (en) | Formulation contg. paroxetine | |
| JPH07507809A (en) | 3-substituted-2-oxindole-1-carboxamide pharmaceutical composition | |
| CN1029771C (en) | Preparation of cantharidin fat-soluble preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 19990303 |